跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/JPRN-jRCT2061220036
JPRN-jRCT2061220036招募中2 期

A Japanese phase II study to evaluate the efficacy and safety of combination therapy of amrubicin and durvalumab in patients with recurrent small cell lung cancer - Aphrodite study

Kato Yuka0 个研究点目标入组 36 人开始时间: 2022年6月22日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
36
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable（—）
性别
All

入选标准

  • •1. Patients who have fully received an explanation and understood the purpose, contents, anticipated effects, and risks of the informed consent form and this study protocol, and who have given their free and voluntary written consent
  • •2. 20 years of age or older at the time of enrollment in this clinical trial
  • •3. ECOG PS of 0 or 1
  • •4. Body weight of over 30kg
  • •5. Patients with a histological or cytological diagnosis of small cell lung cancer. Combined small cell lung cancer will be included in this clinical trial, but LCNEC will not be included in this clinical trial.
  • •6. Patients with extensive-stage small cell lung cancer who are refractory/intolerant to initial chemotherapy and who are undergoing second-line treatment
  • •7. Patients who received at least one cycle of durvalumab or atezolizumab as initial chemotherapy
  • •8. Patients with at least 1 lesion that qualifies as a RECIST 1.1 target lesion

排除标准

  • •1. Patients who have participated during the last 6 months or are currently participating in another clinical trial with an investigational product
  • •2. Patients who have received the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) within 14 days prior to the first dose of the investigational drug
  • •3. Patients with any unresolved toxicity NCI CTCAE Grade >=2 from previous anticancer therapy (excluding alopecia, vitiligo, and laboratory values defined in the inclusion criteria)
  • •4. Patients receiving any concurrent chemotherapy, investigational drugs, biologic or hormonal therapy for cancer treatment
  • •5. Patients who have received radiotherapy treatment (more than 30% of the bone marrow or with a wide field of radiation)within 28 days prior to the first dose of the investigational drug
  • •6. Patients who have undergone major surgical procedure within 28 days prior to the first dose of the investigational drug
  • •7. Patients with a history of allogeneic organ transplantation, hematopoietic stem cell transplantation, or other transplantation therapies
  • •8. Patients with active autoimmune disease, poorly controlled endocrine disease, inflammatory disease, or a confirmed medical history of such disease
  • •9. Patients with uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
  • •10. Patients with a medical history of another primary malignancy

研究者

发起方
Kato Yuka

相似试验

进行中（未招募）
1 期
Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factorsmetastatic pancreatic carcinomaMedDRA version: 18.1Level: LLTClassification code 10033576Term: Pancreas carcinomaSystem Organ Class: 100000004864
EUCTR2011-005471-17-DEKlinikum der Universität München-Großhadern150
进行中（未招募）
2 期
A Clinical Study to evaluate the efficacy and safety of NRC-AN-019 in cancer patients failing prior standard therapies
CTRI/2013/06/003768ATCO Pharma Limited
招募中
2 期
Phase II Clinical Study to evaluate the efficacy and safety of NRC-2694-A
CTRI/2019/06/019649ATCO Pharma Ltd
进行中（未招募）
1 期
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000015841
EUCTR2016-005115-41-HUTransgene S.A.39
进行中（未招募）
1 期
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864
EUCTR2016-005115-41-BETransgene S.A.44